Literature DB >> 30756014

A Case of Primary Gastric Melanoma Exhibiting a Rare BRAF V600R Mutation.

Grainne M Callaghan1, Fergal C Kelleher2, Paul F Ridgway3,4, Stephen Crowther5, Alaa Alakkari1, Barbara M Ryan1,6.   

Abstract

INTRODUCTION: Malignant melanoma of the gastrointestinal tract is usually a metastasis from a cutaneous source. Primary gastric melanoma is an extremely rare clinical entity, with few reported cases worldwide. It is often advanced at time of diagnosis and is associated with a dismal outcome.
BACKGROUND: A 76 year old gentleman presenteded with a one month history of fatigue and exertional dyspnoea. Laboratory investigations indicated an anaemia, with a haemoglobin level of 11.0g/dl. Subsequent gastroscopy visualised a large, atypical, crater-like ulcerated lesion distal to the cardia in the proximal stomach.Provisional histology was suggestive of a poorly differentiated adenocarcinoma but subsequent cyto-morphology and immunophenotyping were consistent with melanoma, with positive S100 protein, HMB45 and Melan A. Further molecular genetic testing revealed a V600R mutation in the BRAF gene, which is the first primary gastric melanoma with this mutation to be reported in the literature. Given the rarity of the findings, an extensive secondary work-up was undertaken, which concluded the diagnosis primary gastric melanoma. DISCUSSION: Primary gastric melanoma is a rare disease that can present similarly to other upper gastrointesinal lesions, with weight loss, abdominal pain, malena, and anaemia. Given its rarity, the pathogenesis is poorly understood. Lesions are often endoscopically atypical. Important points to note would include the absence of a primary lesion, as supported by a full skin examination and PET-CT findings, which can help to delineate the limitation to the stomach, thus helping to inform subsequent management. LEARNING POINTS: Primary gastric melanoma (PGM) is a rare clinical entity.Work-up including skin and ophthalmic examination is important to exclude a primary cutaneous source, as this helps dictate both prognosis and subsequent management, including whether surgical resection is advisable.Immunophenotyping and genetic testing inform management but, despite advances in therapy, the prognosis of PGM and other mucosal melanomas remains poor.

Entities:  

Keywords:  BRAF; Gastric melanoma; malignant melanoma

Year:  2018        PMID: 30756014      PMCID: PMC6346958          DOI: 10.12890/2018_000749

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


INTRODUCTION

Primary gastric melanoma (PGM) is extremely rare, with few reported cases. PGM tends to metastasise early and has a poor outcome. We present the case of a patient whom an extensive work-up concluded PGM, with a rare BRAF V600R mutation. While BRAF mutations are common in cutaneous melanoma[, they are rare in mucosal melanomas, and have not previously been described in a PGM.

CASE DESCRIPTION

A 76-year-old male patient presented with a one-month history of fatigue, exertional dyspnoea and weight loss. He had iron deficiency anaemia. At gastroscopy, there was a large ulcerated lesion in the proximal stomach (Fig. 1). Histological examination revealed extensive lamina propria infiltration by a population of large epithelioid malignant cells. Immunohistochemistry was positive for S100 Protein, HMB-45, and Melan-A, consistent with malignant melanoma. Further genetic analysis revealed a V600R mutation at exon 15 of the BRAF gene.
Figure 1

Endoscopic image of a large ulcerated lesion in the proximal stomach

Work-up, including a full skin examination and ophthalmology review, did not identify another primary source, and no metastatic disease was identified on radiological imaging. The consensus diagnosis of the treating physicians and surgeons was that findings were consistent with PGM. Subsequently, he underwent an open sleeve gastrectomy, and histology confirmed a melanomatous process, with two positive local lymph nodes. Following post-operative recovery and prior to commencement of systemic treatment, a repeat CT scan of the thorax, abdomen and pelvis showed interval progression of the disease in the two-month interval, with new liver metastases and an enlarging left upper quadrant deposit. The patient commenced immunotherapy, but unfortunately died of disease progression within a few months.

DISCUSSION

Melanoma is an aggressive neoplasm that usually occurs in cutaneous sites, but can also arise from other less common sites such as uveal tracts and mucosa. Mucosal melanoma accounts for only 1.3% of all these cases, tends to present with advanced disease, and generally has a very poor prognosis[. PGM, a subtype of mucosal melanoma, is an even rarer occurrence, with only sporadic case reports in the literature[. PGM presents similarly to other upper gastrointestinal lesions, with weight loss, abdominal pain, and melaena. If histology is diagnostic of melanoma, it is important to exclude metastasis from a primary cutaneous or ocular lesion, with full skin examination by a dermatologist and an ophthalmological assessment to outrule another primary source, as this influences both the prognosis and further management, including whether surgical resection is advisable. Detailed radiological imaging is performed to delineate the burden of metastases, if indicated by histology. Genetic testing of melanoma is mandatory as it informs the treatment paradigm, with targeted therapies available for patients exhibiting specific mutations. Ninety per cent of all mutations are acquired, due to the effects of cumulative environmental factors, such as exposure to ultraviolet light. Mucosal melanomas have been found to exhibit different genetic mutations to their cutaneous counterparts, suggesting differing tumour biology[. Approximately 50% of cutaneous melanomas have a BRAF mutation[, whereas BRAF mutations are rare in mucosal melanomas[. The BRAF oncogenic effect is exerted through increased activation of the MAP kinase pathway, leading to uncontrolled cell proliferation[. Several BRAF mutations have been described, with V600E accounting for over 80% of mutations[. The V600R mutation (a substitution of arginine for valine at codon 600 of the BRAF gene) was identified in this patient, and accounts for approximately 4% of all melanoma cases[, and, to our knowledge, has not been previously described in a PGM. There is no clear consensus on the management of PGM. In this case, the disease progressed rapidly despite management with surgery and immunotherapy, consistent with the scanty literature which suggests a uniformly poor prognosis.
  6 in total

Review 1.  BRAF as therapeutic target in melanoma.

Authors:  Claudia Wellbrock; Adam Hurlstone
Journal:  Biochem Pharmacol       Date:  2010-03-27       Impact factor: 5.858

Review 2.  Mucosal melanomas: Site-specific information, comparisons with cutaneous tumors, and differential diagnosis.

Authors:  Nicole R Dominiak; Mark R Wick; M Timothy Smith
Journal:  Semin Diagn Pathol       Date:  2016-04-16       Impact factor: 3.464

Review 3.  BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.

Authors:  C W Wong; Y S Fan; T L Chan; A S W Chan; L C Ho; T K F Ma; S T Yuen; S Y Leung
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

4.  Primary advanced esophago-gastric melanoma: A rare case.

Authors:  Lin Wang; Liang Zong; Hidetsugu Nakazato; Wen-Yue Wang; Chao-Feng Li; Yan-Fen Shi; Guo-Chao Zhang; Tao Tang
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

5.  Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

Authors:  Christine M Lovly; Kimberly Brown Dahlman; Laurel E Fohn; Zengliu Su; Dora Dias-Santagata; Donna J Hicks; Donald Hucks; Elizabeth Berry; Charles Terry; MarKeesa Duke; Yingjun Su; Tammy Sobolik-Delmaire; Ann Richmond; Mark C Kelley; Cindy L Vnencak-Jones; A John Iafrate; Jeffrey Sosman; William Pao
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

6.  The role of BRAF V600 mutation in melanoma.

Authors:  Paolo A Ascierto; John M Kirkwood; Jean-Jacques Grob; Ester Simeone; Antonio M Grimaldi; Michele Maio; Giuseppe Palmieri; Alessandro Testori; Francesco M Marincola; Nicola Mozzillo
Journal:  J Transl Med       Date:  2012-07-09       Impact factor: 5.531

  6 in total
  4 in total

Review 1.  The challenge of primary gastric melanoma: a systematic review.

Authors:  Gregory S Mellotte; Diya Sabu; Mary O'Reilly; Ray McDermott; Anthony O'Connor; Barbara M Ryan
Journal:  Melanoma Manag       Date:  2020-11-23

2.  Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis.

Authors:  Manlio Monti; Massimo Guidoboni; Devil Oboldi; Giulia Bartolini; Federica Pieri; Silvia Ruscelli; Alessandro Passardi; Laura Ridolfi; Francesco De Rosa; Francesco Giulio Sullo; Giovanni Luca Frassineti
Journal:  Therap Adv Gastroenterol       Date:  2021-02-24       Impact factor: 4.409

3.  Primary Gastric Malignant Melanoma in a 68-Year-Old Woman: A Case Report and Review of the Literature.

Authors:  Gabriella Gabos; Elena Daniela Burtea; Sergiu-Cătălin Brici; Florin Costea; Carmen Nicolau
Journal:  Curr Health Sci J       Date:  2022-03-31

4.  Primary malignant melanoma of the stomach: a rare entity.

Authors:  Pradeep Zechariah; Suraj Surendran; Vijay Abraham; Inian Samarasam
Journal:  BMJ Case Rep       Date:  2020-09-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.